Preparing your results

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer.

Nature | Jun 25, 2009

http://www.ncbi.nlm.nih.gov/pubmed/19553991

Genome-wide copy number analyses of human cancers identified a frequent 5p13 amplification in several solid tumour types, including lung (56%), ovarian (38%), breast (32%), prostate (37%) and melanoma (32%). Here, using integrative analysis of a genomic profile of the region, we identify a Golgi protein, GOLPH3, as a candidate targeted for amplification. Gain- and loss-of-function studies in vitro and in vivo validated GOLPH3 as a potent oncogene. Physically, GOLPH3 localizes to the trans-Golgi network and interacts with components of the retromer complex, which in yeast has been linked to target of rapamycin (TOR) signalling. Mechanistically, GOLPH3 regulates cell size, enhances growth-factor-induced mTOR (also known as FRAP1) signalling in human cancer cells, and alters the response to an mTOR inhibitor in vivo. Thus, genomic and genetic, biological, functional and biochemical data in yeast and humans establishes GOLPH3 as a new oncogene that is commonly targeted for amplification in human cancer, and is capable of modulating the response to rapamycin, a cancer drug in clinical use.

Pubmed ID: 19553991 RIS Download

Mesh terms: Animals | Antibiotics, Antineoplastic | Cell Line, Tumor | DNA-Binding Proteins | Female | Gene Knockdown Techniques | Humans | Membrane Proteins | Mice | Mice, Nude | Neoplasms | Protein Kinases | Saccharomyces cerevisiae | Signal Transduction | Sirolimus | TOR Serine-Threonine Kinases | Transcription Factors

Research resources used in this publication

None found

Research tools detected in this publication

None found

Data used in this publication

None found

Associated grants

  • Agency: NIAMS NIH HHS, Id: 5-T32-AR07098-31
  • Agency: NCI NIH HHS, Id: P50 CA090578
  • Agency: NCI NIH HHS, Id: P50 CA093683
  • Agency: NCI NIH HHS, Id: P50 CA093683-06A20011
  • Agency: NCI NIH HHS, Id: P50 CA93683
  • Agency: NCI NIH HHS, Id: R0-1 CA 114277
  • Agency: NIA NIH HHS, Id: R01 AG2400401
  • Agency: NCI NIH HHS, Id: R01 CA093947
  • Agency: NCI NIH HHS, Id: R01 CA093947-08
  • Agency: NCI NIH HHS, Id: R01 CA114277
  • Agency: NCI NIH HHS, Id: R01 CA114277-04
  • Agency: NCI NIH HHS, Id: R01 CA122794
  • Agency: NCI NIH HHS, Id: R01 CA122794
  • Agency: NCI NIH HHS, Id: R01 CA122794-03
  • Agency: NCI NIH HHS, Id: R01 CA93947
  • Agency: NIAMS NIH HHS, Id: T32 AR007098
  • Agency: NIAMS NIH HHS, Id: T32 AR007098-32

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.